SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 7, 2020
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
| Nevada | 001-38543 | 26-1265381 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 400 Water Street, Suite 200, Rochester, MI | 48307 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 248.651.6568
|
___________________________________________________ (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | ||
| Common Stock | OPRX | Nasdaq Capital Market |
SECTION 8 – Other Events
| Item 8.01 | Other Events |
On May 7, 2020, we issued a press release announcing that our chief commercial officer, Steve Silvestro, has been honored with the 2020 PM360 ELITE 100 Award for his organizational leadership and positive impact on the healthcare industry. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits | |
| 99.1 | Press release, dated May 7, 2020 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OptimizeRx Corporation
/s/ Douglas Baker
Douglas Baker
Chief Financial Officer
Date May 8, 2020
3
Exhibit 99.1
OptimizeRx’s Steve Silvestro Honored as Transformational Leader in Healthcare by PM360
ROCHESTER, Mich. – May 7, 2020 – OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, announced its chief commercial officer, Steve Silvestro, has been honored with the 2020 PM360 ELITE 100 Award for his organizational leadership and positive impact on the healthcare industry.
 |
The annual awards program recognizes the 100 most influential people in the healthcare industry as the ELITE, which stand for Exceptional Leaders, Innovators, Transformers, and Entrepreneurs. The award is sponsored by PM360, the premier magazine and online news source for marketing decision makers in the pharmaceutical, biotech, and medical device industries. |
 |
PM360 received hundreds of nominations which were evaluated and selected by the PM360 editorial staff based on accomplishments, testimonials, and supporting evidence that reflected the impact of their efforts.
Silvestro was recognized in the Transformational Leaders category for his exceptional ability to foster positive organizational change, with his profile featured on the PM360 ELITE 100 website and in the publication’s May 2020 issue.
“This well-deserved award reflects Steve’s career-long commitment to improving outcomes for all stakeholders in healthcare, from patient and doctors, to organizations that provide life-saving medications and treatments,” commented OptimizeRx CEO, William Febbo. “Steve has become a trusted advisor to our clients on key strategic initiatives, a mentor among his peers, and a valuable member of our executive team. He has earned deep respect within our organization for his transformational work that has driven the growth and market expansion of our OptimizeRx digital health platform and our ability to deliver the best in connected care.”
CEO and publisher of PM360, Anna Stashower, stated: “At a time when the world is being impacted by a healthcare crisis in the COVID-19 pandemic, it is nice to be able to reflect on the extraordinary work those in the life sciences do to discover, develop, and promote life-saving treatments. Our ELITE winners epitomize the very best of our industry. We are incredibly thankful for everything they do and proud to honor all of their achievements.”
See Steve Silvestro’s PM360 ELITE 100 profile here, and more information about the PM360 ELITE 100 Award at pm360online.com/the-2020-pm360-elite-100.
About OptimizeRx®
OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence and care management. OptimizeRx’s network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support on specialty medications and patient financial assistance directly within a provider’s workflow through leading electronic health platforms. OptimizeRx’s fully integrated platform supports the real-time exchange of information, improving provider knowledge and patient engagement, and ultimately leading to healthier outcomes.
For more information, follow the company on Twitter, LinkedIn or visit www.OptimizeRx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.
OptimizeRx Contact
Doug Baker, CFO
Tel (248) 651-6568 x807
dbaker@optimizerx.com
Media Relations Contact
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070
malejandra@optimizerx.com
Investor Relations Contact
Ron Both, CMA
Tel (949) 432-7557
oprx@cma.team